“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Lupin’s Europe business recorded a growth of 13% with sales of Rs.6,414 million during the year.
The key contributors to growth include the portfolio expansion of Hormosan Pharma, our German subsidiary, new product launches and scaling NaMuscla across U.K., Germany and France. During the year, Hormosan entered into a partnership with Eli Lilly to promote their migraine product Emgality further strengthening Hormosan’s position as a market leader in the cluster headache and migraine segment. In the U.K., we also launched Valproate Semisodium and several ARVs.
